Interim results from the phase II COCOON trial show a proactive skincare approach can cut dermatologic adverse events by 50% in patients receiving frontline therapy for EGFR-mutant non-small cell lung cancer (NSCLC). The study, led by Bishal Tiwari of Nassau University Medical Center and Asmita… (as reported), frames the interim readout as a practical mitigation strategy during EGFR inhibitor treatment. Dermatologic toxicities are among the most common dose-limiting issues in EGFR-mutant NSCLC regimens, and they can drive treatment interruptions or dose modifications. A 50% reduction in such events, if confirmed in later analyses, would position supportive care as a meaningful lever for maintaining dose intensity. The trial’s interim nature suggests continued data collection ahead of any definitive practice guidance, but the reported magnitude makes it stand out for oncology operations and patient management workflows.